Payment overview · 2025
General Payments
$128.72
8 reported records · 6 companies
Healthcare provider profile · identity verified
Jose Lopez, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1265694186
Verified facts
What the public records show
CMS Open Payments records show Jose Lopez, MD received $128.72 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.34 | 26.7% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $22.01 | 17.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.05 | 14.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.80 | 14.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.40 | 14.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.12 | 12.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $128.72 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $22.01 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.05 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 516 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 471 | 130 |
| Losartan Potassium | Losartan Potassium | 441 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 142 |
| Lisinopril | Lisinopril | 338 | 107 |
| Duloxetine Hcl | Duloxetine Hcl | 323 | 94 |
| Gabapentin | Gabapentin | 278 | 113 |
| Omeprazole | Omeprazole | 238 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 76 |
| Metformin Hcl | Metformin Hcl | 231 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 225 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 80 |
| Fluticasone Propionate | Fluticasone Propionate | 211 | 81 |
| Simvastatin | Simvastatin | 186 | 56 |
| Glipizide | Glipizide | 185 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 55 |
| Metformin Hcl Er | Metformin Hcl | 179 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 60 |
| Ozempic | Semaglutide | 155 | 34 |
| Glipizide Er | Glipizide | 147 | 46 |
| Eliquis | Apixaban | 141 | 40 |
| Tramadol Hcl | Tramadol Hcl | 137 | 50 |
| Montelukast Sodium | Montelukast Sodium | 134 | 41 |
| Famotidine | Famotidine | 131 | 47 |
| Furosemide | Furosemide | 127 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 35 |
| Trazodone Hcl | Trazodone Hcl | 113 | 38 |
| Carvedilol | Carvedilol | 109 | 40 |
| Sertraline Hcl | Sertraline Hcl | 109 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 46 |
| Januvia | Sitagliptin Phosphate | 93 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 90 | 32 |
| Lorazepam | Lorazepam | 87 | 22 |
| Spironolactone | Spironolactone | 85 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 24 |
| Trulicity | Dulaglutide | 79 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 23 |
| Jardiance | Empagliflozin | 71 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 24 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 23 |
| Alendronate Sodium | Alendronate Sodium | 64 | 23 |
| Benazepril Hcl | Benazepril Hcl | 61 | 19 |
| Finasteride | Finasteride | 58 | 17 |
| Enalapril Maleate | Enalapril Maleate | 57 | 18 |
| Alprazolam | Alprazolam | 54 | 24 |
| Allopurinol | Allopurinol | 52 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 20 |
| Valsartan | Valsartan | 47 | 13 |
| Meloxicam | Meloxicam | 46 | 20 |
| Potassium Chloride | Potassium Chloride | 44 | 15 |
| Rybelsus | Semaglutide | 44 | 12 |
| Nifedipine Er | Nifedipine | 42 | 15 |
| Celecoxib | Celecoxib | 41 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 12 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 18 |
| Azithromycin | Azithromycin | 38 | 35 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Myrbetriq | Mirabegron | 37 | 11 |
| Terazosin Hcl | Terazosin Hcl | 36 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 11 |
| Methylprednisolone | Methylprednisolone | 34 | 24 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 12 |
| Baclofen | Baclofen | 31 | 11 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 23 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Diclofenac Potassium | Diclofenac Potassium | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Ondansetron Odt | Ondansetron | 24 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | 12 |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Linzess | Linaclotide | 18 | 11 |
| Constulose | Lactulose | 17 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $128.72 · 8 records | AstraZeneca Pharmaceuticals LP | Azstarys, BREZTRI, Dexcom G6 Transmitter, QULIPTA, The Cologuard Plus Collection Kit, UBRELVY, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error